Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 98

1.

Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil.

Schaier M, Scholl C, Scharpf D, Hug F, Bönisch-Schmidt S, Dikow R, Schmitt WH, Schwenger V, Zeier M, Sommerer C.

Rheumatology (Oxford). 2010 Nov;49(11):2061-7. doi: 10.1093/rheumatology/keq238. Epub 2010 Jul 29.

PMID:
20671023
[PubMed - indexed for MEDLINE]
Free Article
2.

Proton pump inhibitors reduce mycophenolate exposure in heart transplant recipients-a prospective case-controlled study.

Kofler S, Shvets N, Bigdeli AK, König MA, Kaczmarek P, Deutsch MA, Vogeser M, Steinbeck G, Reichart B, Kaczmarek I.

Am J Transplant. 2009 Jul;9(7):1650-6. doi: 10.1111/j.1600-6143.2009.02682.x. Epub 2009 Jun 10.

PMID:
19519820
[PubMed - indexed for MEDLINE]
Free Article
3.

Proton pump inhibitor co-medication reduces mycophenolate acid drug exposure in heart transplant recipients.

Kofler S, Deutsch MA, Bigdeli AK, Shvets N, Vogeser M, Mueller TH, Meiser B, Steinbeck G, Reichart B, Kaczmarek I.

J Heart Lung Transplant. 2009 Jun;28(6):605-11. doi: 10.1016/j.healun.2009.03.006.

PMID:
19481022
[PubMed - indexed for MEDLINE]
4.

The proton pump inhibitor pantoprazole and its interaction with enteric-coated mycophenolate sodium in transplant recipients.

Kofler S, Wolf C, Shvets N, Sisic Z, Müller T, Behr J, Sohn HY, Vogeser M, Shipkova M, Meiser B, Steinbeck G, Reichart B, Kaczmarek I.

J Heart Lung Transplant. 2011 May;30(5):565-71. doi: 10.1016/j.healun.2010.12.003. Epub 2011 Jan 21.

PMID:
21256049
[PubMed - indexed for MEDLINE]
5.

Proton pump inhibitor co-medication reduces active drug exposure in heart transplant recipients receiving mycophenolate mofetil.

Doesch AO, Mueller S, Konstandin M, Celik S, Erbel C, Kristen A, Frankenstein L, Koch A, Ehlermann P, Zugck C, Katus HA.

Transplant Proc. 2010 Dec;42(10):4243-6. doi: 10.1016/j.transproceed.2010.09.047.

PMID:
21168674
[PubMed - indexed for MEDLINE]
6.

The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study.

Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S.

Ther Drug Monit. 2011 Feb;33(1):120-3. doi: 10.1097/FTD.0b013e318206a1b1.

PMID:
21192310
[PubMed - indexed for MEDLINE]
7.

Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy.

Chiarelli LR, Molinaro M, Libetta C, Tinelli C, Cosmai L, Valentini G, Dal Canton A, Regazzi M.

Br J Clin Pharmacol. 2010 Jan;69(1):38-50. doi: 10.1111/j.1365-2125.2009.03542.x.

PMID:
20078611
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes.

Budde K, Glander P, Krämer BK, Fischer W, Hoffmann U, Bauer S, Grohmann J, Neumayer HH, Arns W.

Transplantation. 2007 Feb 27;83(4):417-24.

PMID:
17318074
[PubMed - indexed for MEDLINE]
9.

Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients.

Glander P, Hambach P, Braun KP, Fritsche L, Waiser J, Mai I, Neumayer HH, Budde K.

Int J Clin Pharmacol Ther. 2003 Oct;41(10):470-6.

PMID:
14703953
[PubMed - indexed for MEDLINE]
10.

Influence of lansoprazole and rabeprazole on mycophenolic acid pharmacokinetics one year after renal transplantation.

Miura M, Satoh S, Inoue K, Kagaya H, Saito M, Suzuki T, Habuchi T.

Ther Drug Monit. 2008 Feb;30(1):46-51. doi: 10.1097/FTD.0b013e31816337b7.

PMID:
18223462
[PubMed - indexed for MEDLINE]
12.

Evaluation of inosin-5'-monophosphate dehydrogenase activity during maintenance therapy with tacrolimus.

Maiguma T, Yosida T, Otsubo K, Okabe Y, Sugitani A, Tanaka M, Oishi R, Teshima D.

J Clin Pharm Ther. 2010 Feb;35(1):79-85. doi: 10.1111/j.1365-2710.2009.01072.x.

PMID:
20175815
[PubMed - indexed for MEDLINE]
13.

Comparison of inosine-monophosphate-dehydrogenase activity in patients with enteric-coated mycophenolate sodium or mycophenolate mofetil after renal transplantation.

Rath T, Küpper M.

Transplant Proc. 2009 Jul-Aug;41(6):2524-8. doi: 10.1016/j.transproceed.2009.06.124.

PMID:
19715967
[PubMed - indexed for MEDLINE]
14.

Pharmacokinetics and pharmacodynamics of mycophenolic acid in stable renal transplant recipients treated with low doses of mycophenolate mofetil.

Brunet M, Martorell J, Oppenheimer F, Vilardell J, Millán O, Carrillo M, Rojo I, Corbella J.

Transpl Int. 2000;13 Suppl 1:S301-5.

PMID:
11112019
[PubMed - indexed for MEDLINE]
15.

Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism.

Sombogaard F, van Schaik RH, Mathot RA, Budde K, van der Werf M, Vulto AG, Weimar W, Glander P, Essioux L, van Gelder T.

Pharmacogenet Genomics. 2009 Aug;19(8):626-34. doi: 10.1097/FPC.0b013e32832f5f1b.

PMID:
19617864
[PubMed - indexed for MEDLINE]
16.

Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation.

Mourad M, Malaise J, Chaib Eddour D, De Meyer M, König J, Schepers R, Squifflet JP, Wallemacq P.

Clin Chem. 2001;47(7):1241-8.

PMID:
11427455
[PubMed - indexed for MEDLINE]
Free Article
17.

Pharmacokinetics of enteric-coated mycophenolate sodium: comparative study in patients with autoimmune disease and renal allograft.

Neumann I, Fuhrmann H, Kanzler M, Fang IF, Jaeger A, Graf H, Bayer P, Kovarik J.

Expert Opin Pharmacother. 2008 Apr;9(6):879-86. doi: 10.1517/14656566.9.6.879.

PMID:
18377332
[PubMed - indexed for MEDLINE]
18.

Unexpected augmentation of mycophenolic acid pharmacokinetics in renal transplant patients receiving tacrolimus and mycophenolate mofetil in combination therapy, and analogous in vitro findings.

Zucker K, Rosen A, Tsaroucha A, de Faria L, Roth D, Ciancio G, Esquenazi V, Burke G, Tzakis A, Miller J.

Transpl Immunol. 1997 Sep;5(3):225-32.

PMID:
9402690
[PubMed - indexed for MEDLINE]
19.

Differences in clearance of mycophenolic acid among renal transplant recipients, hematopoietic stem cell transplant recipients, and patients with autoimmune disease.

de Winter BC, Mathot RA, Sombogaard F, Neumann I, van Hest RM, Doorduijn JK, van Gelder T.

Ther Drug Monit. 2010 Oct;32(5):606-14. doi: 10.1097/FTD.0b013e3181efd715.

PMID:
20720518
[PubMed - indexed for MEDLINE]
20.

Inosine monophosphate dehydrogenase activity depends on plasma concentrations of mycophenolic acid and its glucuronides in kidney transplant recipients.

Mino Y, Naito T, Otsuka A, Ozono S, Kagawa Y, Kawakami J.

Clin Chim Acta. 2009 Nov;409(1-2):56-61. doi: 10.1016/j.cca.2009.08.016. Epub 2009 Aug 31.

PMID:
19723513
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk